Health Secretary Wes Streeting has criticised pharmaceutical companies as “shortsighted” after talks over drug pricing for the NHS broke down last week. The two sides failed to reach an agreement on financial terms for the supply of medicines, escalating a row that threatens to strain relations between the government and the industry.
Streeting accused drug firms of undermining their relationship with the government by rejecting a pricing offer that he described as fair. The health secretary warned that the standoff could have long-term consequences for the availability of new treatments on the NHS.
The dispute centres on the cost of branded medicines, with the government seeking to cap spending growth. Pharmaceutical companies argue that the proposed terms would stifle innovation and investment in the UK, potentially leading to delays in patient access to cutting-edge drugs.
Negotiations are expected to continue, but the impasse highlights the ongoing tension between the need to control public spending and the desire to maintain the UK as an attractive market for life sciences. Both sides have expressed a willingness to find a resolution, though no new talks have been scheduled.
